2024-11-25
The research and development and market layout of domestic HPV vaccines are in a stage of rapid development, which has not only made important breakthroughs in technology, but also shown strong momentum in market expansion.
Studies have shown that 5-8 years after HPV vaccination, there is a significant decrease in the prevalence of high-risk HPV types in young women. The HPV vaccine works by using synthetic L1 late protein virus-like particles (VLPs) as target antigens, which have a natural spatial structure and can stimulate the body to produce high titers of serum neutralizing antibodies to neutralize the virus and help activate tumor-specific killer T lymphocytes to clear viral infection.
